Our Bold Goal for the Pancreatic Cancer Survival Rate - Cassadie Moravek

Pancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.

However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030.

"So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."